Overview of Siltegra

Quick Facts

Property	Description
Active ingredient	Sildenafil (as the citrate salt)
Form	Film-coated tablets
Route of administration	Oral (by mouth)
Pharmacological class	Phosphodiesterase type 5 (PDE5) inhibitor
Origin	Synthetic (Pyrazolo-pyrimidinone derivative)
General Purpose	To facilitate and sustain enhanced blood flow

Siltegra: Definition and Pharmacological Identity

Siltegra is a prescription-only medicine containing the active substance Sildenafil (INN). It is classified pharmacologically as a highly selective Phosphodiesterase type 5 (PDE5) inhibitor. Its efficacy in modulating vascular tone is clinically recognized.

The core identity of Sildenafil, a synthetic pyrazolo-pyrimidinone derivative, confirms its status as an engineered molecule designed for a specific therapeutic pathway. As a prescription-only medicine (Rx), Siltegra is specifically authorized for use in adult populations requiring targeted enhancement of blood flow, a focus that differentiates it from over-the-counter products.

What is Siltegra's Composition and Form?

Siltegra is provided as a film-coated tablet intended for oral administration, with Sildenafil formulated as the citrate salt as its sole active component. The presentation as a film-coated tablet provides a standardized, reliable method for systemic absorption following ingestion, a feature common to many drugs of its class. Sildenafil is an orally active, potent, and selective inhibitor, underscoring the product's quality as a standardized, single-active compound.

Understanding the General Purpose of PDE5 Inhibitors

The general therapeutic aim of Sildenafil is to facilitate vasodilation—the widening of blood vessels—in specific tissues, thereby improving and sustaining blood flow. This effect is achieved through the drug's fundamental action of inhibiting the PDE5 enzyme, allowing the natural signaling molecule cGMP to accumulate. This selective physiological action results in the smooth muscle relaxation necessary for the vascular change. The main function of Siltegra is to enable the body's natural response mechanisms to operate more effectively when specific vascular support is required.

What side effects are possible with Siltegra?

Possible Side Effects and Safety Information

The safety profile of Siltegra (sildenafil) is organized in official regulatory documents according to the frequency and type of adverse reactions observed in clinical use and post-marketing surveillance. This information establishes the documented risk characteristics of the medicine without providing clinical advice or usage instructions.

Frequency-Classified Adverse Reactions

The most frequent adverse events are generally related to the drug's mechanism of action, which involves vasodilation. Official regulatory labels classify side effects into standard frequency categories.

Classification	Examples of Documented Reactions
Very Common (ge 1/10)	Headache
Common (ge 1/100 to < 1/10)	Flushing, dyspepsia, visual disturbances (e.g., cyanopsia, blurred vision), dizziness, nasal congestion, nausea

Adverse reactions are formally grouped into affected System-Organ Classes, including Nervous System Disorders, Eye Disorders, Vascular Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights specific, less frequent adverse reactions with significant clinical importance. These include Priapism (prolonged erection lasting over four hours), reports of sudden Non-arteritic anterior ischaemic optic neuropathy (NAION) (vision loss), and rare, temporally associated serious cardiovascular events (e.g., myocardial infarction, stroke).

Safety Restrictions: A definitive constraint is the absolute contraindication for use in individuals taking any form of nitrates or nitric oxide donors due to the risk of severe, potentially life-threatening hypotension. Furthermore, caution is advised in patients with severe hepatic impairment or specific anatomical penile deformations, as documented in the prescribing information.

Overdose and Emergency Response

Overdose Map: Overdose and when to Seek Help — Official Regulatory Information for Siltegra

Overdose Scope

Category	Official Regulatory Statement
Documented Overdose Presentations	Over-exposure may present with decreased blood pressure (hypotension), syncope, and a prolonged erection (priapism). The incidence and severity of adverse events are increased at higher exposures.
Physiological Systems Affected	Cardiovascular system (hypotension, syncope), Urogenital system (priapism).
Exposure-related Factors	Higher plasma concentrations and increased exposure/risk are associated with doses significantly exceeding recommended therapeutic limits.
Population-specific Overdose Notes	Patients aged 65 or over, those with hepatic impairment, and those with severe renal impairment are documented to have higher plasma levels of the active substance in an overdose situation.
Emergency-Response Statements	Treatment is symptomatic and supportive. No specific antidote is known. Management may include measures to support circulation, such as the use of intravenous crystalloid fluids or pressor agents.
When immediate medical help is required	Seek immediate medical assistance/emergency treatment if an erection persists longer than four hours. Seek prompt medical attention for a sudden decrease or loss of vision or hearing.

Overdose Classifications (High-Level)

Category	Official Regulatory Statement
Severity Classification	Priapism is categorized as severe, as failure to treat immediately may lead to penile tissue damage and permanent loss of potency.
Regulatory Basis	Based on the FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).
Overdose-Context Constraints	Hemodialysis is not expected to accelerate clearance due to high plasma protein binding.

Resulting Overdose Structure

Official overdose statements:

An overdose may result in severe hypotension, syncope, and potentially a prolonged erection (priapism).
Immediate medical assistance must be sought if an erection persists for more than four hours to prevent permanent tissue damage.
No specific antidote is available; management must be symptomatic and supportive, including measures to stabilize circulation and monitor vital signs.

Connection to the overall overdose profile: Regulatory documents define the Sildenafil overdose profile by documenting expected manifestations, such as a drop in blood pressure, and establishing a mandatory emergency action trigger for the life-threatening outcome of priapism. Since the official profile confirms the absence of a specific antidote, it strictly directs management toward immediate external support and symptomatic treatment to address the observed physiological effects and prevent long-term injury.

Therapeutic Uses of Siltegra

The therapeutic application of Siltegra (Sildenafil) is centered on addressing physical symptoms arising from specific issues in blood flow regulation, generally applied across domains where additional symptomatic support is needed. It is primarily relevant for easing symptoms associated with two main condition categories: Erectile Dysfunction (ED) in adult men and Pulmonary Arterial Hypertension (PAH) in both adults and children.

The medicine supports functional stability by addressing symptoms related to organ-specific functional stress. This use primarily focuses on alleviating debilitating symptoms like reduced exercise ability and fatigue, which interfere with daily functioning.

Supportive Therapeutic Benefits

In cases of ED, the medication is typically sought on an on-demand basis to address symptom clusters of inadequate penile rigidity. The key benefit is providing functional support that may assist with maintaining this aspect of sexual health and contributing to improved patient comfort. For PAH, Siltegra is used for targeted, chronic management to address heightened symptoms related to systemic imbalance, supports the patient during difficult episodes by easing distress, and may help patients cope more steadily with symptom fluctuations during this progressive disorder.

Quick Fact: Relief for Key Symptom Domains
Primary Focus	Vascular functional support in adult men for ED and chronic pulmonary symptom management for PAH.
Use Context	Applied in situations requiring short-term symptomatic assistance (ED) or sustained management (PAH).
Main Benefit	Contributes to improved comfort and assists with maintaining functional stability in symptomatic periods.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Siltegra — Official Regulatory Information

Eligibility Scope	Official Regulatory Classification
Populations for whom use is allowed	Adult men (18 years and older) for Erectile Dysfunction.
Populations for whom use is contraindicated	Patients using any form of organic nitrates or nitric oxide donors. Patients with known hypersensitivity to sildenafil. Patients with severe hepatic impairment. Individuals with hypotension (BP lt 90/50 mmHg). Patients with recent extbfstroke or extbfmyocardial infarction (heart attack). Those with certain retinal disorders (e.g., retinitis pigmentosa) or history of extbfNAION (vision loss).
Age-related eligibility rules	Not indicated for individuals under 18 years for Erectile Dysfunction. Chronic use in pediatric PAH patients is extbfnot recommended due to safety concerns. Older adults (65 years) may require cautious dose selection.
Condition-specific eligibility rules	Use requires caution or dose adjustment in severe renal impairment and mild to moderate hepatic impairment. Use is extbfnot recommended in extbfPulmonary Veno-Occlusive Disease (PVOD) and severe unstable cardiac conditions.
Pregnancy and lactation eligibility status	Use is extbfnot recommended during both pregnancy and lactation.

Connection to the overall eligibility profile: Official regulatory documents define non-eligibility primarily through absolute contraindications linked to severe cardiovascular risk (nitrate co-use, recent stroke/MI, hypotension) and specific disease states (severe hepatic impairment, retinal disorders). For other populations, eligibility is restricted, mandating caution or lower starting doses due to factors like reduced organ function or age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Siltegra (Sildenafil) is strictly defined by its metabolic clearance via hepatic enzymes and its pharmacodynamic activity on vascular tone, as stated in government regulatory documents.

Contraindicated Combinations

Co-administration is strictly prohibited due to the risk of severe, potentially life-threatening hypotension resulting from powerful additive vasodilatory effects. The prohibited combinations listed are:

Organic Nitrates: In any form, including both long-acting and intermittent use.
Riociguat: This soluble guanylate cyclase (sGC) stimulator must not be taken concurrently with Sildenafil.

Pharmacokinetic Interactions

Sildenafil is cleared predominantly by the hepatic enzyme CYP3A4 (major route) and secondarily by CYP2C9. This metabolic pathway makes the medicine sensitive to co-administered enzyme modulators:

CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) increase Sildenafil’s systemic exposure (AUC). Elevated exposure may require adjustments to manage plasma concentrations.
CYP3A4 Inducers (e.g., Rifampin, St. John’s Wort) decrease Sildenafil’s systemic exposure.

Mechanism of Action

Siltegra contains sildenafil, a molecule that functions as a competitive inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).

Pharmacodynamic Mechanism

Siltegra's primary biological target is the PDE5 enzyme, which is abundant in vascular and visceral smooth muscle, including the pulmonary vasculature and the corporal tissue of the penis. The molecular structure of sildenafil mimics that of cGMP, allowing it to bind to the catalytic site of PDE5.

This binding event prevents the hydrolysis and subsequent degradation of the intracellular second messenger, cGMP. The intracellular pathway modification results in elevated cGMP concentrations within the smooth muscle cells.

Increased cGMP levels trigger a downstream cascade involving the activation of cGMP-dependent protein kinase (PKG). PKG-mediated phosphorylation of various proteins ultimately leads to a decrease in intracellular calcium ion concentration and the deactivation of myosin light chain kinase.

This cellular process culminates in smooth muscle relaxation and resultant vasodilation in the targeted tissues. The system-level physiological consequence is a reduction in vascular resistance and an increase in local blood flow in the pulmonary circulation and the corpus cavernosum.

Dosage and Administration Information

Siltegra's usage protocol is determined by the specific condition being managed, establishing two distinct administration patterns.

Administration for Erectile Dysfunction (ED)

For the management of ED, the medicine is administered orally and used on an as-needed (on-demand) basis. The typical starting dose is 50 mg, which may be adjusted within a range of 25 mg up to a maximum of 100 mg. Dosing must not exceed once per day. The tablet may be taken with or without food; however, consumption with a high-fat meal may delay the onset of activity.

Administration for Pulmonary Arterial Hypertension (PAH)

In contrast, the treatment of PAH requires a scheduled, chronic regimen. The standard oral dose is 20 mg, administered three times a day (t.i.d.) with doses separated by approximately four to six hours. The medicine may also be administered via intravenous (IV) injection at a 10 mg dose when the patient is temporarily unable to use the oral route. The oral suspension form, approved for PAH, requires reconstitution with water and shaking before each administration.

Population-Specific Adjustments

Dose adjustments are required for specific populations. A lower starting dose of 25 mg is generally considered for ED use in older adults (65 years and over), as well as in patients with severe hepatic or renal impairment. Furthermore, administrative constraints exist when the medicine is co-administered with certain strong inhibitors, where the dose must not exceed 25 mg in a 48-hour period.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Siltegra: Patient Summary

This overview describes the types of clinical studies that have been evaluated for Siltegra, what those studies observed in patient groups, and where the current evidence is limited or still uncertain. This is a descriptive summary of the research landscape and does not determine whether an individual will respond similarly to the patterns observed in the studies.

Evidence for use in Erectile Dysfunction (ED)

This section summarizes the structure of the clinical research for ED, describing the types of randomized, placebo-controlled trials that form the evidence base and the specific patient-reported outcomes and functional scores that were evaluated in adult men.

The research for this use primarily consists of multiple short-term, randomized, double-blind, placebo-controlled trials (RCTs). These are studies commonly used in research for evaluating a treatment. Researchers examined how outcomes related to physical discomfort and function were evaluated in the observed populations. The main outcomes monitored included specific patient-reported measures of erectile function scores (e.g., IIEF) and the number of attempts at intercourse logged as successful by participants. The research also examined how outcomes reflecting daily functioning were evaluated in subgroups such as men with diabetes mellitus. Despite the volume of research, follow-up durations were limited in the primary trials.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

This section outlines the design of the main intermediate-term trials and long-term observational studies conducted for PAH. The content details the primary endpoints monitored in these studies, such as functional exercise capacity and tracking of clinical worsening events.

The evidence base includes intermediate-term, randomized, placebo-controlled trials, which were evaluated in both adult and pediatric patient groups. These trials examined outcomes related to systemic or functional imbalance, such as functional exercise capacity (measured by tests like the 6-Minute Walk Distance). Studies monitored measurements, and findings indicate a difference in functional exercise capacity between the treatment and placebo groups. Long-term research for PAH is ongoing to characterize outcomes across all adult patient subgroups. For pediatric patients, the evidence is limited by a finding where a specific signal regarding dose and all-cause mortality was observed in some studies during long-term follow-up.

Frequently Asked Questions (FAQ)

Common questions about Siltegra (FAQ)

Q: How long does it typically take to start noticing the intended effects of Siltegra?

Official product information states that the medicine is absorbed rapidly after it is taken. Maximum concentrations in the blood are typically reached within about one hour (median time). Taking the medicine along with food may slow down the rate at which it starts working.

Q: What is the duration of action for Siltegra once it has been taken?

Studies report that the medicine's terminal half-life—the time it takes for half the drug to be cleared from the body—is typically between three and five hours. This indicates that the medicine's concentration is slowly cleared from the body over several hours.

Q: Are there any major food groups or specific dietary restrictions to be aware of while using Siltegra?

Regulatory documents indicate that consuming the medicine with a high-fat meal may delay the onset of its effects. Official information specifies that grapefruit juice may affect the enzyme CYP3A4, potentially leading to increased medicine levels in the blood.

Q: Can Siltegra be taken by someone who has a history of heart problems?

Regulatory documents list a number of heart-related conditions as contraindications, including recent stroke or myocardial infarction (heart attack). For a history of other heart problems, caution is advised, and these individuals may require specific evaluations as described in official guidelines due to the medicine's vasodilating effects.

Q: Is it possible for Siltegra to interact with over-the-counter pain relievers like ibuprofen or aspirin?

Official safety information includes a general caution regarding individuals with bleeding disorders or active peptic ulceration. This is noted in conjunction with documented studies on platelet aggregation.

Q: Do studies suggest that Siltegra is more effective in certain age groups?

Clinical trials for the medicine included adults across a wide range of ages. While a lower starting dose is typically considered for older adults (65 years and over), the efficacy data does not generally indicate differences in effectiveness across the age groups studied.

Q: Does Siltegra require a special diet or lifestyle change to work properly?

Regulatory documents mention specific interactions with a high-fat meal and caution regarding the use of alcohol. Beyond these specific substance interactions, the official label does not mandate a 'special diet' for the medicine to work.

Q: Is there a generic version of Siltegra available, and is it the same active ingredient?

Siltegra contains the active ingredient sildenafil. Regulatory bodies confirm that generic versions contain the same active substance and are demonstrated to be bioequivalent to the brand-name medicine.

Q: Can older adults safely use Siltegra, and is there any specific information for them?

Dosage adjustments are not generally required for older adults (65 years and over) receiving the pulmonary arterial hypertension (PAH) formulation. However, a lower starting dose for the erectile dysfunction formulation is generally considered in older adults, as described in regulatory guidance.

Q: Are there any documented interactions between Siltegra and herbal supplements or vitamins?

Yes, the official drug label explicitly names the herbal supplement St. John’s Wort as a substance that may decrease the amount of the medicine in the body. This is part of a broader caution regarding co-administration with substances that affect the CYP3A4 enzyme.

Q: Does taking Siltegra cure the condition, or does it only manage symptoms?

Regulatory documents consistently describe the medicine as working to manage symptoms and restore function. The medicine is officially indicated for the treatment of conditions, not as a permanent cure for the underlying diseases.

Q: Are there any long-term side effects that are described in the research for Siltegra?

While primary trials for the erectile dysfunction indication were short-term, later studies suggested efficacy was maintained. For the pulmonary arterial hypertension indication, long-term research identified a safety concern regarding dose and mortality in pediatric patients, which led to a specific recommendation against chronic pediatric use.

Q: Can women use Siltegra, and are there different considerations for them?

The medicine is not approved for the treatment of erectile dysfunction in women, but it is approved for pulmonary arterial hypertension (PAH) in both men and women. Use is not recommended during pregnancy or breastfeeding for either indication.

Q: Is Siltegra addictive or does it cause dependence?

The active substance, sildenafil, is not classified as a controlled substance in the U.S. Regulatory documents do not contain information indicating that physical addiction or dependence is a noted characteristic of the drug.

Q: What specific medical tests are recommended before starting Siltegra?

Prescribing information advises that physicians should carefully consider whether patients with certain underlying medical conditions, especially severe heart problems, could be negatively affected by the drug's action on blood vessels. The official label states that the medicine is not recommended for individuals for whom sexual activity is inadvisable due to their underlying cardiovascular status.

Q: Does the effectiveness of Siltegra decrease over time with continued use?

While some clinical studies suggest the effectiveness is maintained over periods of one year or longer, other research has suggested a potential loss of efficacy with prolonged use in some patients. Evidence regarding tolerance is mixed across different studies.

Q: What precautions are generally advised when first starting Siltegra?

Official information advises on situations requiring caution, which include patients who may be predisposed to priapism (a prolonged erection) and those with certain anatomical penile deformations. Caution is also noted when initiating use in patients taking an alpha-blocker due to the risk of symptomatic hypotension.

Q: Is Siltegra a Schedule/Controlled substance?

No, the active ingredient in Siltegra, sildenafil, is not classified as a controlled substance under the U.S. Controlled Substances Act. This means it is not assigned a DEA Schedule.

Q: Can Siltegra be crushed or split for ease of swallowing?

The medicine is supplied as a film-coated tablet and is typically intended to be swallowed whole. There are no general instructions advising to crush or split the tablets.

Q: What is the pediatric use classification for Siltegra?

The medicine is not indicated for the treatment of erectile dysfunction in individuals under 18 years of age. For pediatric patients with pulmonary arterial hypertension (PAH), chronic use is not recommended due to safety signals observed in long-term follow-up studies.

Q: Are there alternatives to Siltegra for the same condition?

Regulatory documents indicate that the medicine belongs to the PDE5 inhibitor class. Other medicines in the same class, and other types of treatment, are mentioned in regulatory documents as being used for the conditions that Siltegra is indicated to treat.

Q: Is it generally true that higher doses of Siltegra lead to a greater chance of side effects?

Clinical trial data and controlled studies indicate that taking single doses higher than the maximum recommended dose has resulted in a generally increased incidence and severity of the usual adverse events. These can include headache, flushing, and dizziness.

Q: Does Siltegra affect fertility or reproductive health in men or women?

Non-clinical studies have investigated sildenafil's effects on fertility in men, specifically looking at sperm characteristics. For women, use is not recommended during either pregnancy or breastfeeding.

Q: How is the safety profile of Siltegra described in official documentation?

Official regulatory documents organize the safety profile by classifying reported adverse reactions based on how often they occur (e.g., Very Common, Common). They are also grouped by the affected System-Organ Class, such as Nervous System Disorders and Vascular Disorders.

Q: Is it required to take Siltegra at the same time every day?

The requirement varies based on the condition being treated. For erectile dysfunction, the medicine is taken on an as-needed basis. For the pulmonary arterial hypertension indication, it is used on a scheduled, chronic regimen administered multiple times per day, typically with doses separated by a specific time frame.

Q: Are there any known interactions with grapefruit juice?

Yes, official drug information indicates that grapefruit juice may cause the level of the medicine in the bloodstream to increase due to its effect on the CYP3A4 enzyme. This may raise the potential for adverse effects.

Q: Does Siltegra cause drowsiness or affect the ability to drive or operate machinery?

The regulatory label advises that the medicine can cause dizziness and visual disturbances like blurred vision. Patients should be aware of how they react to the medicine before engaging in activities like driving or operating machinery.

Q: What is the half-life of Siltegra in the body?

The terminal half-life of the active ingredient, sildenafil, is reported in regulatory and scientific literature to typically fall within the range of three to five hours in healthy adults.

Q: Does Siltegra have a specific drug monitoring requirement (e.g., blood tests)?

Official labeling does not typically mandate specific routine blood tests for the general population. However, it advises that caution and specific evaluations should be performed by a healthcare provider for patients with pre-existing severe conditions, particularly cardiovascular disorders, before starting the therapy.

How should Siltegra be stored and disposed of?

How to Store and Dispose of Siltegra?

Siltegra (sildenafil citrate) must be stored strictly according to official regulatory requirements to maintain its stability.

Storage Conditions

Temperature and Environment: The tablets require storage at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The medication must be kept away from light and should not be stored in moist or damp areas, such as a bathroom.

Container and Safety: The medication must be kept in the original container it came in, and the container must be tightly closed. It must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. Precautions should be taken to prevent the product from being released into surface water or the sewage system.

Siltegra